<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148495</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0116</org_study_id>
    <nct_id>NCT04148495</nct_id>
  </id_info>
  <brief_title>Intravenous Acetaminophen and Morphine Versus Intravenous Morphine Alone for Acute Pain in the Emergency Department</brief_title>
  <acronym>ADAMOPA</acronym>
  <official_title>Intravenous Acetaminophen and Morphine Versus Intravenous Morphine Alone for Acute Pain in the Emergency Department: a Multicenter Randomized Controlled Double-blind Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In emergency medicine, acute pain is a common reason for consultation. It is recommended that
      patients in moderate to severe pain should receive a combination of intravenous acetaminophen
      and morphine. However, the data are sparse to support this strategy. Thus, the purpose of our
      research is to test non-inferiority of IV morphine alone versus IV acetaminophen and morphine
      in a multicenter, randomized, controlled double blind trial in ED patients with moderate to
      severe acute pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to assess whether IV morphine alone is non inferior to combination IV
      acetaminophen and morphine for the management of moderate to severe pain in the ED. Numeric
      rating scale pain score will be compared between those who receive morphine alone and who
      will receive acetaminophen and morphine at 15, 30, 45 and 60 min post first injection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">June 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of numeric rating scale pain scores between those who received morphine alone and who received combination of acetaminophen and morphine at 30 minutes.</measure>
    <time_frame>30 minutes</time_frame>
    <description>The Numerical Pain Rating Scale measures the perception of pain intensity with an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of numeric rating scale pain scores between those who received morphine alone and who received the combination of acetaminophen and morphine at 10min, 20 min, 45 min and 60min.</measure>
    <time_frame>60 minutes</time_frame>
    <description>The Numerical Pain Rating Scale measures the perception of pain intensity with an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated cumulative dose of morphine in both arms at a dose -by-weight (mg/kg) dose during the first 30 minutes</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and intensity of adverse reactions: nausea, vomiting, respiratory failure, hypotension</measure>
    <time_frame>through study completion, an average of 60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">572</enrollment>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine IV and the placebo of acetaminophen IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine IV and acetaminophen IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo of acetaminophen IV</intervention_name>
    <description>Mophine IV: Initial loading dose of 0.1 mg/kg followed by bolus of 0.05 mg/kg every 10 minutes as reported by the recommandation of experts of the french society of urgency care.
Placebo of acetaminophen IV: Sodium chloride 0.9%</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen IV</intervention_name>
    <description>Mophine IV: Initial loading dose of 0.1 mg/kg followed by bolus of 0.05 mg/kg every 10 minutes as reported by the recommandation of experts of the french society of urgency care.
Acetaminophen IV: 1 g</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 Years and older

          -  Moderate to severe acute pain, defined as a numeric rating scale score greater than or
             equal to 5.

          -  Conscious patient

          -  Clinical stability (systolic blood pressure &gt; 90 or &lt; 180 mmHg, heart rate &gt; 50 or &lt;
             150/min, and respiratory rate &gt; 10 or &lt; 30/min).

          -  Out of guardianship and/or tutorship

          -  Affiliated to the social security plan.

        Exclusion Criteria:

          -  Pregnancy and Breast-feeding

          -  Patient Unable to give numeric rating scale scores

          -  Patient with a weight strictly less than 50kg.

          -  acute pulmonary edema, acute respiratory failure

          -  Acute coronary syndrome or unbalanced ischemic heart disease in progress.

          -  Acute alcoholic intoxication.

          -  Patient who received morphine or acetaminophen for the current acute pain episode.

          -  No possibility of having venous access

          -  History of chronic pain during treatment.

          -  Allergy, intolerance or know contraindication to paracetamol or morphine or to an
             excipient.

          -  Renal or hepatic insufficiency.

          -  Association with buprenorphine, nalbuphine and pentazocine.

          -  Patient unable or unable to give written consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume CATTIN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume CATTIN, Doctor</last_name>
    <phone>+33 2 40 08 73 78</phone>
    <email>guillaume.cattin@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuel MONTASSIER, Doctor</last_name>
    <phone>+33 2 53 48 20 38</phone>
    <email>Emmanuel.MONTASSIER@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marion LE POTTIER, Doctor</last_name>
      <phone>(+33) 2 41 35 36 37</phone>
      <email>marion.lePottier@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marion LE POTTIER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel GALINSKI</last_name>
      <phone>(+33) 5 56 79 48 26</phone>
      <email>michel.galinski@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Michel GALINSKI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Châteaubriant Hôspital</name>
      <address>
        <city>Châteaubriant</city>
        <zip>44146</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas HOURDIN, Doctor</last_name>
      <phone>(+33) 2 40 55 88 88</phone>
      <email>nicolas.hourdin@ch-cnp.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas HOURDIN, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maxime MAIGNAN</last_name>
      <phone>(+33) 4 76 76 67 84</phone>
      <email>mmaignan@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Maxime MAIGNAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Roche-sur-Yon Hospital</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valérie DEBIERRE, Doctor</last_name>
      <phone>(+33) 2 51 44 62 05</phone>
      <email>valerie.debierre@chd-vendee.fr</email>
    </contact>
    <contact_backup>
      <last_name>Doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>Valérie DEBIERRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tahar CHOUIEB, Doctor</last_name>
      <phone>(+33) 3 83 85 98 46</phone>
      <email>t.chouihed@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Tahar CHOUIEB, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CATTIN, Dr</last_name>
      <phone>+33 2 40 08 73 78</phone>
      <email>guillaume.cattin@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuel MONTASSIER, Dr</last_name>
      <phone>+33 2 53 48 20 38</phone>
      <email>Emmanuel.MONTASSIER@chu-nantes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>La Pitié-Salpêtrière University Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yonathan FREUND, Doctor</last_name>
      <phone>(+33) 1 42 16 00 00</phone>
      <email>Yonathanfreund@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yonathan FREUND, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Morphine</keyword>
  <keyword>acetaminophen</keyword>
  <keyword>Acute pain</keyword>
  <keyword>Analgesics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

